Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China

BACKGROUND AND OBJECTIVE: The programmed death 1 and ligand (PD‐1/PD‐L1) inhibitors have significantly altered therapeutic perspectives on non‐small‐cell lung cancer (NSCLC). However, their efficacy and safety are unknown since direct clinical trials have not yet been performed on them. It is also n...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Meng‐Meng, Chen, Si‐Ying, Yang, Bo, Wang, Yan, Han, Rui‐Ying, An, Meng‐Na, Dong, Ya‐lin, You, Hai‐Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446572/
https://www.ncbi.nlm.nih.gov/pubmed/34382361
http://dx.doi.org/10.1002/cam4.4191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446572/
https://www.ncbi.nlm.nih.gov/pubmed/34382361
http://dx.doi.org/10.1002/cam4.4191

Ejemplares similares